Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN) Meeting Abstract
| Authors: | Beltran, H.; Dowlati, A.; Jain, P.; Johnson, M. L.; Sanborn, R. E.; Thompson, J. R.; Mamdani, H.; Schenk, E. L.; Aggarwal, R. R.; Sankar, K.; Gramza, A. W.; Anand, B. S.; Choudhury, N. J. |
| Abstract Title: | Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN) |
| Meeting Title: | 2024 ASCO Genitourinary Cancers Symposium |
| Keywords: | 261-492-199-2823; 613-225-2782; 261-492-199-2823-7422-11198; 613-225-2577-2545; 283-197-6219; 283-183-138-226; 613-615-646-4685-2424; 38092-34755; 38092-21757; 38092-21759 |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2024 Jan 25-27 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-02-01 |
| Language: | English |
| ACCESSION: | WOS:001266676900094 |
| DOI: | 10.1200/JCO.2024.42.4_suppl.121 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 121 -- Source: Wos |
